摘要
目的:了解南京地区口服降糖药的应用近况和发展趋势,为临床合理使用口服降糖药提供参考。方法:根据长江流域医药情报研究所提供的南京地区2011-2013年口服降糖药的销售数据,采用限定日剂量分析法,对该地区34家医院近三年口服降糖药的销售金额、用药频度(DDDs)和限定日费用(DDC)等进行统计分析。结果:销售金额排名前三位的药物是阿卡波糖、格列美脲、二甲双胍,DDDs排名前三位的药物是格列美脲、二甲双胍、格列齐特,总销售金额和总DDDs均呈逐年增长趋势,销售金额与DDDs的序号比值在0.3-2.0之间。结论:2011-2013年南京地区口服降糖药需求量逐年增加,口服降糖药使用符合安全、有效、经济的用药原则,建议治疗时根据药物的特点进行选择,以改善糖尿病的代谢异常和防治并发症。
Objective: To evaluate the utilization of oral hypoglycemic drugs in 34 hospitals of Nanjing to provide clinical reference for the drug rational use. Methods: According to the sales data of oral hypoglycemic drugs in 34 hospitals of Nanjing from 2011 to 2013,the utilization of oral hypoglycemic drugs was analyzed retrospectively in respect of consumption sum,DDDs and defined daily cost( DDC) by daily dose limit analysis method. Results: The top 3 oral hypoglycemic drugs in the list of consumption sum were acarbose,glimepiride and metformin. In terms of DDDs,glimepiride,metformin and gliclazide ranked the top 3. The consumption sum and DDDs of oral hypoglycemic drugs were increased year by year in Nanjing. The ratio of serial number of consumption sum and DDDs was from 0. 3 to 2. 0. Conclusion: The demanded quantity of oral hypoglycemic drugs is increased year by year from 2011 to 2013. The application conforms to the safe,effective and economic principle. The drugs should be chosen according to the drug characteristics in order to improve the abnormal glucose metabolism and prevent and treat the complications.
出处
《中国药师》
CAS
2014年第12期2104-2107,共4页
China Pharmacist
关键词
口服降糖药
用药分析
用药频度
销售金额
Oral hypoglycemic drugs
Application analysis
DDDs
Consumption sum